TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02266472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: single dose of metformin given as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin/metformin
Description: Single dose empagliflozin/metformin given as fixed-dose combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: single dose of empagliflozin given as tablet
Study: NCT02353442

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior shoulder mobilizations
Description: A second investigator performed 5min of posterior capsule shoulder mobilization for the experimental group, 3times/week during 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External rotators strengthening
Description: Individuals performed 3x10 repetitions of external rotators strengthening in sidelying position 3times/week during 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ultrasound
Description: A second investigator performed 5min of placebo ultrassound for the control group, 3times/week during 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scapular squeezing
Description: Individuals performed 3x10 repetitions scapular squeezing exercise 3times/week during 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Upper trapezius stretching
Description: Individuals performed 3x30s of upper trapezius stretching, 3times/week during 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Capsule Stretching
Description: Individuals performed 3x30s of posterior capsule stretching, 3times/week during 4 weeks.
Study: NCT05150808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IRS insecticide: Vectron T500
Description: public health insecticide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IRS insecticide: Vectron T500
Description: public health insecticide
Study: NCT02233101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Tranexamic Acid
Description: patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Tranexamic Acid
Description: Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative
Study: NCT01665820

Intervention type: DEVICE
Intervention: Auscultate with electronic or mechanical stethoscope (3M Littmann)

Intervention type: DEVICE
Intervention: Auscultate with electronic or mechanical stethoscope (3M Littmann)
Study: NCT00907517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion
Study: NCT03852628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Buprenex and 380mg Vivitrol
Description: Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SL pill qd, IM injection q4weeks)
Description: Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
Study: NCT02429024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Reveal® Mobile APP
Description: Diabetes management application for use on a mobile phone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Verio® Flex BGMS
Description: Blood Glucose Monitoring System (BGMS)
Study: NCT02375594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise in park equipment
Study: NCT01970475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABP 501
Description: Solution for subcutaneous injection in pre-filled syringe

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Solution for subcutaneous injection in pre-filled syringe
Study: NCT02092480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: If I Were Jack
Description: The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
Study: NCT04535323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Autologous Platelet-rich Plasma
Description: Given via injection
Study: NCT01100060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin (AZ) microsphere
Description: AZ microsphere (2000 mg) single dose on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test chloroquine (CQ) formulation
Description: Test CQ formulation, 620 mg CQ base, single dose on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin (AZ)
Description: AZ IR 4 x 500 mg tablets, single dose on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloroquine (CQ)
Description: CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
Study: NCT02204137

Intervention type: OTHER
Intervention: Falls Risk Questionnaire

Intervention type: OTHER
Intervention: Cancer and Aging Research Group Geriatric Assessment

Intervention type: OTHER
Intervention: Falls Efficacy Scale-International (FES-1)

Intervention type: OTHER
Intervention: Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)
Study: NCT00728117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feeding
Description: Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feeding
Description: Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fasting
Description: Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fasting
Description: Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
Study: NCT02220504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment discontinuation
Description: Withdrawal of antipsychotic medication to stabilized patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance antipsychotic treatment
Description: Maintenance antipsychotic medication to stabilized patients.
Study: NCT01233882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Single dose of 200 mg of bosutinib in subjects with normal renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Single dose of 200 mg of bosutinib in subjects with mild renal impairment
Study: NCT04259203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Erickson hypnosis
Description: Erickson hypnosis sessions performed by an experienced hypnotherapist, according to a pre-established protocol : 5 sessions (1 per week). Between each session : exercise of auto-hypnosis by the patient himself, at home
Study: NCT03762239

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purifying the air with a Pure Airbox device (Zonair 3D)
Description: Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Using a sham air purifier (same device without filters)
Description: Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
Study: NCT01233882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Single dose of 200 mg of bosutinib in subjects with moderate renal impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Single dose of 200 mg of bosutinib in subjects with severe renal impairment
Study: NCT00366301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine injection
Description: Once daily for 14 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine injection
Description: Once daily for 14 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Up to 4 pils per day (2g per day) maximum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Up to 4 pils per day (2g per day) maximum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill
Description: Up to 4 pills per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Up to 4 pills per day
Study: NCT02710695

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will receive a standardized 10 minute discussion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: This group will receive a standardized 10 minute discussion
Study: NCT02579018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One hour supervised exercise session
Description: All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One hour supervised exercise session
Description: All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One hour supervised exercise session
Description: All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
Study: NCT02207439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir (Viracept®) 1250 mg
Description: Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Period 2: Concurrent Chemoradiation (70 Gy over 7 weeks) with Nelfinavir (1250 mg bid)
Study: NCT01964521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Transfer Ag
Description: A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
Study: NCT01091623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training
Study: NCT03452605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cocoa flavanol supplementation
Description: cocoa flavanols (containing 196 mg epicatechin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cocoa flavanol supplementation
Description: cocoa flavanols (containing 196 mg epicatechin)
Study: NCT03458559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radium-223 chloride
Description: Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhenium-188-HEDP
Description: Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
Study: NCT00476619

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erythropoeitin
Description: Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
Study: NCT02092246

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound machine
Description: Use of ultrasound machine guidance for accurate needle placement into the knee joint

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unguided injection
Description: Needle placement will take place without ultrasound machine guidance
Study: NCT03485274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: oral medication taken once daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
Study: NCT03446105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based behavioral intervention
Description: Achieving Wellness After Kancer in Early life (AWAKE) is a behavioral intervention that includes a smartphone app and coaching. AWAKE contains eight modules, and participants will complete the one module every week. App functioning will facilitate weekly homework assignments and include health education messaging, the ability to track progress toward goals over time via self-monitoring and graphical depictions of progress, audio-recordings of guided imagery exercises and relaxation exercises (e.g., progressive muscle relaxation), videos of topic-related inspirational material, and a portal for interacting with the coach. The coach will call each intervention participant weekly. Each coaching session will last roughly 30 minutes and involve four segments that will correspond to the module for the week. The coach will send daily text messages to participants encouraging their goal pursuits and providing other sources of support related to that week's homework.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control group
Description: The attention control group will receive the same components as the intervention group, but the educational modules will contain different content than those receiving the AWAKE intervention.
Study: NCT01663779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided radial artery catheterization.
Description: Radial artery catheters will be placed with the assistance of bedside ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind insertion of radial artery catheterization
Description: Radial artery catheters will be placed by the palpation technique only.
Study: NCT03360409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACD
Description: Undertake anterior cervical discectomy without fusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Description: anterior cervical discectomy with fusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACDA
Description: anterior cervical discectomy with arthroplasty
Study: NCT03065088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aLIFE
Description: The aLiFE programme is taught by an instructor during six home visits and 3 phone calls during the 6-month intervention period. The programme will be personalised by use of an initial balance and strength assessment (aLiFE assessment tool). The participants assigns activities to his or her daily activities, and during subsequent home visits, the number of activities and task demands are upgraded. Participants will be taught how to select opportunities themselves to embed activities into their individual daily routine, and how to progress over time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eLIFE
Description: The eLIFE includes a personalised ICT-administered training schedule using the activities developed in aLiFE, delivered in the form of video clips, pictures and text/verbal instructions on a smartphone and smartwatch application. Personalisation of activity content will be decided based on a phenotype tool and initial difficulty level is decided through the aLiFE assessment tool. In addition, a virtual instructor teaches the participants how to carry out the eLiFE programme. The user receives motivational messages and feedback, and there will be a possibility for social interaction between the participants. The instructors teach the eLiFE participants the programme during 4 home visits and 3 phone calls during the 6 month intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The control group follows the World Health Organization's recommendations of physical activity. The control participants will receive one home visit and be given a written letter with the activity recommendations.
Study: NCT02410798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransLoc electrode
Description: Patients will have 2 electrodes placed in either side of the diaphragm (total 4 electrodes) during their primary surgery.
Study: NCT00464516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily for 14 days orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: once daily for 14 days orally
Study: NCT02050919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study: NCT02674360

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SDM Training
Study: NCT02050919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study: NCT01361620

Intervention type: DRUG
Group type: OTHER
Intervention: aspirin
Description: aspirin 81mg, 7-10 days
Study: NCT03222258

Intervention type: BEHAVIORAL
Intervention: Early palliative care
Description: Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.

Intervention type: BEHAVIORAL
Intervention: Early palliative care
Description: Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.

Intervention type: BEHAVIORAL
Intervention: Routine hospice care
Description: Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated

Intervention type: BEHAVIORAL
Intervention: Routine hospice care
Description: Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated

Intervention type: BEHAVIORAL
Intervention: Routine hospice care
Description: Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
Study: NCT03942380

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liquid biopsy
Description: The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liquid biopsy
Description: The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA
Study: NCT01900574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.